A Phase 1 interventional study of MLN0128 in Advanced Solid Malignancies, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-01.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase I, open label, Dose Escalation study of oral administration of single agent MLN0128 in participants with Advanced Malignancies followed by an Expansion Phase in participants with renal cell carcinoma, endometrial cancer or urothelial cancer who have measurable disease.
The drug being tested in this study is called MLN0128. MLN0128 is being tested to treat people who have Advanced Malignancies.
The study enrolled approximately 198 patients. Participants were assigned to one of the following dose regimens in the Dose Escalation Phase to establish the Maximum Tolerated Dose (MTD):
MLN0128 capsule, orally, once daily (QD) or Once weekly (QW) in the Dose Escalation Phase until MTD was established.
Once MTD was determined, participants were then enrolled in the Dose Expansion Phase to receive:
This multi-centre trial was conducted worldwide. The overall time to participate in this study was approximately 244 weeks. Participants will make multiple visits to the clinic, and were contacted by telephone OR plus a final visit after last dose of study drug for a follow-up assessment.
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additionally, to be eligible for the Dose Expansion portion of the study:
Exclusion Criteria:
Please note that there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.
Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MLN0128 2 mg, 4 mg, 6 mg or 7 mg, capsule, orally, once daily (QD) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 52.1 weeks).
Drug: MLN0128
MLN0128 7 mg, 10 mg, 15 mg, 20 mg, 30 mg or 40 mg capsule, orally, once weekly (QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 139.4 weeks).
Drug: MLN0128
MLN0128 6 mg, 9 mg, 12 mg, 16 mg or 20 mg capsule, orally, once daily every 3 days a week (QDx3d QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 129.4 weeks).
Drug: MLN0128
MLN0128 7 mg, 10 mg or 13 mg capsule, orally, once daily every 5 days a week (QDx5d QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 161.9 weeks).
Drug: MLN0128
MLN0128 5 mg, capsule, orally, QD in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 98.3 weeks).
Drug: MLN0128
MLN0128 30 mg, capsule, orally QW in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 240 weeks).
Drug: MLN0128
MLN0128 40 mg, capsule, orally, QW in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 100.1 weeks).
Drug: MLN0128
MLN0128 capsules
Also known as: INK128, TAK-128
Dose Escalation Phase: Maximum Tolerated Dose (MTD)
MTD was defined as the highest dose level of MLN0128 at which no more than 1 out of 6 evaluable participants experienced a DLT during the first cycle (28 days) of therapy.
Time frame: Cycle 1 (28 Days)
Dose Escalation Phase: Number of Participants With Dose Limiting Toxicities (DLTs)
DLTs were defined as MLN0128-related treatment-emergent adverse events (TEAEs) that occurred within the Cycle 1 (first 28 days of treatment) as per Common Terminology Criteria for Adverse Events (CTCAE): Any ≥Grade 3 or non-hematologic toxicity except for Grade 3 nausea and/or vomiting and diarrhea, Grade 3 hyperglycemia lasting ≤ 14 days, Grade 3 rash lasting ≤ 3 days; Grade 4 neutropenia lasting \>7 days in the absence of growth factor support; Grade 4 neutropenia of any duration associated with fever ≥38.5 degree celsius and/or systemic infection; Any other Grade 4 hematologic toxicity; Inability to administer at least 75% of planned doses of MLN0128 within Cycle 1 due to drug-related toxicity and any clinically significant occurrence that the investigators and sponsor agreed would place participants at an undue safety risk.
Time frame: Cycle 1 (28 days)
Number of Participants Experiencing One or More Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Resulting in Discontinuation of MLN0128 and Fatal AEs Within 30 Days of Last Dose of Study Drug
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
Time frame: First dose of study drug through 30 days after the administration of the last dose of study drug (Up to approximately 244 weeks)
Dose Expansion: Objective Response Rate (ORR)
ORR is defined as the percentage of participants who achieved complete response (CR) or partial response (PR based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. CR is defined as disappearance of all target lesions and PR was defined of at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD and for non-target lesions. Data was categorized as per type of cancer.
Time frame: From the first dose of study drug up to disease progression or death (Up to approximately 240 weeks)
Dose Expansion Phase: Duration of Objective Response
Duration of objective response is defined as the number of months from the start date of CR or PR (whichever occurred first) based on RECIST Criteria version 1.1 to the first date of objectively documented progressive disease (PD) for participants who achieved CR or PR. PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).
Time frame: From the first dose of study drug up to disease progression or death (Up to approximately 240 weeks)
Dose Expansion: Duration of Stable Disease (SD)
Duration of SD was evaluated for participants with best response of SD and is defined as number of months from date of first dose to date of PD. As per RECIST 1.1, SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PR was defined of at least a 30% decrease in sum of longest diameter (LD) of target lesions, taking as reference the baseline sum LD and for non-target lesions. PD is defined as at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study (this includes baseline sum if that is smallest on study).
Time frame: From the first dose of study drug up to disease progression or death (Up to approximately 240 weeks)
Cmax: Maximum Observed Plasma Concentration for MLN0128
Time frame: Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Ctrough: Observed Concentration at the End of a Dosing Interval
Time frame: Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Terminal Phase Elimination Half-life (T1/2) for MLN0128
Time frame: Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MLN0128
Time frame: Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for MLN0128
Time frame: Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Tmax: Time to Maximum Observed Plasma Concentration for MLN0128
Time frame: Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Percentage Area Under Plasma Concentration Time Curve Extrapolated
Time frame: Pre-dose and multiple time-points up to 8 hours post-dose on Day 1 of Cycles 1 and 2
Percentage Change From Baseline in Eukaryotic Initiation Factor 4E-binding Protein 1 (P4EBP1), Serine/Threonine Protein Kinase B (PAKT) and Ribosomal Protein S6 (PS6)
P4EBP, PAKT and PS6 were assayed in skin biopsies. A negative percentage change from Baseline indicates improvement.
Time frame: Baseline, Cycle 1 Week 2
Participants took part in the study at 15 investigative sites in Spain and the United States from 4 January 2010 to 7 February 2019.
| Milestone | MLN0128 QD | MLN0128 QW | MLN0128 QDx3d QW | MLN0128 QDx5d QW | MLN0128 5 mg QD | MLN0128 30 mg QW | MLN0128 40 mg QW |
|---|---|---|---|---|---|---|---|
| Started | 31 | 30 | 33 | 22 | 39 | 17 | 26 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 31 | 30 | 33 | 22 | 39 | 17 | 26 |
| Withdrew: Disease progression | 15 | 20 | 20 | 15 | 23 | 10 | 12 |
| Withdrew: Adverse event | 11 | 4 | 7 | 6 | 7 | 3 | 1 |
| Withdrew: Subject decision | 5 | 3 | 3 | 1 | 2 | 3 | 6 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 3 | 2 | 0 | 7 | 1 | 7 |
MTD was defined as the highest dose level of MLN0128 at which no more than 1 out of 6 evaluable participants experienced a DLT during the first cycle (28 days) of therapy.
| milligrams (mg) | MLN0128 QD | MLN0128 QW | MLN0128 QDx3d QW | MLN0128 QDx5d QW |
|---|---|---|---|---|
| Dose Escalation Phase: Maximum Tolerated Dose (MTD) | 6 | 40 | 9 | 7 |
DLTs were defined as MLN0128-related treatment-emergent adverse events (TEAEs) that occurred within the Cycle 1 (first 28 days of treatment) as per Common Terminology Criteria for Adverse Events (CTCAE): Any ≥Grade 3 or non-hematologic toxicity except for Grade 3 nausea and/or vomiting and diarrhea, Grade 3 hyperglycemia lasting ≤ 14 days, Grade 3 rash lasting ≤ 3 days; Grade 4 neutropenia lasting \>7 days in the absence of growth factor support; Grade 4 neutropenia of any duration associated with fever ≥38.5 degree celsius and/or systemic infection; Any other Grade 4 hematologic toxicity; Inability to administer at least 75% of planned doses of MLN0128 within Cycle 1 due to drug-related toxicity and any clinically significant occurrence that the investigators and sponsor agreed would place participants at an undue safety risk.
| Participants | MLN0128 QD | MLN0128 QW | MLN0128 QDx3d QW | MLN0128 QDx5d QW |
|---|---|---|---|---|
| Dose Escalation Phase: Number of Participants With Dose Limiting Toxicities (DLTs) | 7 | 2 | 6 | 7 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.
| Participants | MLN0128 QD | MLN0128 QW | MLN0128 QDx3d QW | MLN0128 QDx5d QW | MLN0128 5 mg QD | MLN0128 30 mg QW | MLN0128 40 mg QW |
|---|---|---|---|---|---|---|---|
| TEAE | 31 | 30 | 33 | 22 | 39 | 17 | 26 |
| SAE | 13 | 10 | 17 | 10 | 19 | 6 | 9 |
| AEs Resulting in Discontinuation of MLN0128 | 11 | 4 | 7 | 6 | 7 | 3 | 2 |
| Fatal AEs within 30 Days of Last Dose Study Drug | 1 | 1 | 2 | 0 | 0 | 2 | 1 |
ORR is defined as the percentage of participants who achieved complete response (CR) or partial response (PR based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. CR is defined as disappearance of all target lesions and PR was defined of at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD and for non-target lesions. Data was categorized as per type of cancer.
| percentage of participants | MLN0128 5 mg QD | MLN0128 30 mg QW | MLN0128 40 mg QW |
|---|---|---|---|
| Cancer Type: Renal | 15 | 13 | 15 |
| Cancer Type: Endometrial | 9 | 0 | 0 |
| Cancer Type: Bladder | 0 | 0 | 0 |
Duration of objective response is defined as the number of months from the start date of CR or PR (whichever occurred first) based on RECIST Criteria version 1.1 to the first date of objectively documented progressive disease (PD) for participants who achieved CR or PR. PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).
| months | MLN0128 5 mg QD | MLN0128 30 mg QW | MLN0128 40 mg QW |
|---|---|---|---|
| Dose Expansion Phase: Duration of Objective Response | 8.90 (3.48 to 23.06) | 56.05 (56.05 to 56.05) | 20.73 (20.24 to 21.22) |
Duration of SD was evaluated for participants with best response of SD and is defined as number of months from date of first dose to date of PD. As per RECIST 1.1, SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PR was defined of at least a 30% decrease in sum of longest diameter (LD) of target lesions, taking as reference the baseline sum LD and for non-target lesions. PD is defined as at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study (this includes baseline sum if that is smallest on study).
| months | MLN0128 5 mg QD | MLN0128 30 mg QW | MLN0128 40 mg QW |
|---|---|---|---|
| Dose Expansion: Duration of Stable Disease (SD) | 3.68 (0.95 to 14.88) | 2.20 (0.76 to 5.45) | 3.55 (1.18 to 13.08) |
| ng/mL | MLN0128 2 mg QD | MLN0128 4 mg QD | MLN0128 6 mg QD | MLN0128 7 mg QD | MLN0128 7 mg QW | MLN0128 10 mg QW | MLN0128 15 mg QW | MLN0128 20 mg QW | MLN0128 30 mg QW | MLN0128 40 mg QW | MLN0128 6 mg QDx3dQW | MLN0128 9 mg QDx3d QW | MLN0128 12 mg QDx3d QW | MLN0128 16 mg QDx3d QW | MLN0128 20 mg QDx3dQW | MLN0128 7 mg QDx5dQW | MLN0128 10 mg QDx5dQW | MLN0128 13 mg QDx5dQW |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 13.7 (12.30 to 16.30) | 20.5 (9.54 to 35.70) | 48.9 (18.60 to 75.60) | 67.8 (21.10 to 143.00) | 43.6 (16.20 to 94.40) | 75.9 (43.60 to 139.00) | 80.2 (24.30 to 173.00) | 136.6 (66.80 to 217.00) | 174.0 (101.00 to 259.00) | 193.8 (57.90 to 358.00) | 88.5 (72.90 to 115.00) | 82.9 (25.00 to 111.00) | 124.3 (50.90 to 320.00) | 78.5 (35.20 to 184.00) | 194.0 (118.00 to 300.00) | 46.9 (18.80 to 79.00) | 48.5 (22.60 to 76.50) | 110.1 (42.30 to 181.00) |
| Cycle 2 Day 1 | 16.2 (12.00 to 22.70) | 22.1 (11.90 to 35.90) | 39.4 (24.00 to 76.40) | 65.0 (28.20 to 130.00) | 66.7 (55.80 to 77.60) | 40.5 (22.40 to 58.50) | 66.9 (47.70 to 87.90) | 134.00 (134.00 to 134.00) | 142.6 (96.70 to 222.00) | 249.8 (140.00 to 394.00) | 60.0 (52.50 to 74.40) | 87.7 (46.80 to 118.00) | 115.1 (93.40 to 143.00) | 113.6 (42.50 to 292.00) | 183.00 (183.00 to 183.00) | 60.1 (23.50 to 126.00) | 60.0 (32.00 to 95.70) | 96.50 (96.50 to 96.50) |
| ng/mL | MLN0128 2 mg QD | MLN0128 4 mg QD | MLN0128 6 mg QD | MLN0128 7 mg QD | MLN0128 7 mg QW | MLN0128 10 mg QW | MLN0128 15 mg QW | MLN0128 20 mg QW | MLN0128 30 mg QW | MLN0128 40 mg QW | MLN0128 6 mg QDx3dQW | MLN0128 9 mg QDx3d QW | MLN0128 12 mg QDx3d QW | MLN0128 16 mg QDx3d QW | MLN0128 20 mg QDx3dQW | MLN0128 7 mg QDx5dQW | MLN0128 10 mg QDx5dQW | MLN0128 13 mg QDx5dQW |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 0.9 (0.00 to 2.76) | 1.2 (0.00 to 2.48) | 3.5 (0.00 to 8.84) | 4.4 (1.15 to 9.22) | — | — | — | — | — | — | 2.5 (0.00 to 5.01) | 6.8 (0.00 to 16.80) | 9.9 (1.83 to 22.90) | 8.1 (0.00 to 21.50) | 44.7 (6.35 to 123.00) | 3.1 (2.02 to 4.48) | 3.6 (0.00 to 10.10) | 21.7 (5.85 to 43.70) |
| Cycle 2 Day 1 | 4.5 (1.48 to 9.76) | 3.7 (0.00 to 10.30) | 4.5 (3.07 to 9.37) | 3.0 (1.24 to 6.23) | — | — | — | — | — | — | 10.3 (0.00 to 25.10) | 10.8 (5.03 to 25.50) | 4.4 (3.34 to 5.38) | 10.0 (0.00 to 27.10) | 11.40 (11.40 to 11.40) | 5.2 (1.82 to 11.20) | 3.0 (1.08 to 4.68) | 6.58 (6.58 to 6.58) |
| hours | MLN0128 2 mg QD | MLN0128 4 mg QD | MLN0128 6 mg QD | MLN0128 7 mg QD | MLN0128 7 mg QW | MLN0128 10 mg QW | MLN0128 15 mg QW | MLN0128 20 mg QW | MLN0128 30 mg QW | MLN0128 40 mg QW | MLN0128 6 mg QDx3dQW | MLN0128 9 mg QDx3d QW | MLN0128 12 mg QDx3d QW | MLN0128 16 mg QDx3d QW | MLN0128 20 mg QDx3dQW | MLN0128 7 mg QDx5dQW | MLN0128 10 mg QDx5dQW | MLN0128 13 mg QDx5dQW |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 10.3 (10.30 to 10.30) | 7.4 (5.27 to 8.22) | 6.3 (4.86 to 10.40) | 6.2 (5.66 to 6.23) | 6.47 (6.47 to 6.47) | 5.8 (5.72 to 5.95) | 9.4 (6.99 to 11.90) | 5.7 (4.11 to 11.60) | 5.5 (5.30 to 6.94) | 7.1 (4.07 to 12.70) | 5.5 (5.15 to 5.93) | 7.9 (6.53 to 8.12) | 6.4 (4.71 to 11.10) | 7.2 (4.59 to 9.52) | 5.5 (5.10 to 5.84) | 7.8 (5.26 to 9.38) | 6.5 (4.72 to 10.10) | 8.7 (8.20 to 9.16) |
| Cycle 2 Day 1 | 8.1 (7.49 to 8.75) | 9.7 (9.47 to 11.70) | 7.9 (5.83 to 8.06) | 4.9 (3.99 to 7.85) | 5.6 (4.91 to 6.19) | — | 8.01 (8.01 to 8.01) | 4.57 (4.57 to 4.57) | 5.7 (5.08 to 6.35) | 5.6 (4.29 to 9.02) | 9.1 (6.05 to 12.10) | 7.0 (6.01 to 7.85) | 4.9 (4.63 to 5.11) | 6.4 (3.61 to 10.30) | 6.28 (6.28 to 6.28) | 6.8 (6.18 to 7.14) | 5.6 (4.19 to 7.58) | 6.42 (6.42 to 6.42) |
| ng*hr/mL | MLN0128 2 mg QD | MLN0128 4 mg QD | MLN0128 6 mg QD | MLN0128 7 mg QD | MLN0128 7 mg QW | MLN0128 10 mg QW | MLN0128 15 mg QW | MLN0128 20 mg QW | MLN0128 30 mg QW | MLN0128 40 mg QW | MLN0128 6 mg QDx3dQW | MLN0128 9 mg QDx3d QW | MLN0128 12 mg QDx3d QW | MLN0128 16 mg QDx3d QW | MLN0128 20 mg QDx3dQW | MLN0128 7 mg QDx5dQW | MLN0128 10 mg QDx5dQW | MLN0128 13 mg QDx5dQW |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 185.00 (185.00 to 185.00) | 205.3 (145.00 to 269.00) | 390.6 (263.00 to 608.00) | 459.5 (195.00 to 585.00) | 440.00 (440.00 to 440.00) | 609.0 (241.00 to 977.00) | 1014.5 (179.00 to 1850.00) | 1172.7 (563.00 to 2190.00) | 1316.3 (759.00 to 2290.00) | 2149.8 (844.00 to 4310.00) | 494.0 (411.00 to 577.00) | 725.2 (388.00 to 903.00) | 922.8 (383.00 to 1470.00) | 820.1 (389.00 to 1220.00) | 1245.0 (1080.00 to 1410.00) | 326.2 (240.00 to 423.00) | 388.5 (231.00 to 761.00) | 941.5 (483.00 to 1400.00) |
| Cycle 2 Day 1 | — | — | — | — | 371.0 (354.00 to 388.00) | — | 510.00 (510.00 to 510.00) | 1030.00 (1030.00 to 1030.00) | 1427.5 (745.00 to 2110.00) | 2876.6 (903.00 to 6110.00) | — | — | — | — | — | — | — | — |
| ng*hr/mL | MLN0128 2 mg QD | MLN0128 4 mg QD | MLN0128 6 mg QD | MLN0128 7 mg QD | MLN0128 7 mg QW | MLN0128 10 mg QW | MLN0128 15 mg QW | MLN0128 20 mg QW | MLN0128 30 mg QW | MLN0128 40 mg QW | MLN0128 6 mg QDx3dQW | MLN0128 9 mg QDx3d QW | MLN0128 12 mg QDx3d QW | MLN0128 16 mg QDx3d QW | MLN0128 20 mg QDx3dQW | MLN0128 7 mg QDx5dQW | MLN0128 10 mg QDx5dQW | MLN0128 13 mg QDx5dQW |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 65.4 (64.00 to 66.80) | 65.3 (51.60 to 89.80) | 95.30 (95.30 to 95.30) | — | 72.80 (72.80 to 72.80) | 106.00 (106.00 to 106.00) | — | — | — | — | 162.00 (162.00 to 162.00) | 207.5 (198.00 to 217.00) | — | 130.2 (93.40 to 167.00) | — | — | 221.00 (221.00 to 221.00) | — |
| Cycle 2 Day 1 | — | 62.2 (56.30 to 68.00) | — | — | — | 105.00 (105.00 to 105.00) | — | — | — | — | 182.00 (182.00 to 182.00) | — | — | 197.00 (197.00 to 197.00) | — | — | — | — |
| hours | MLN0128 2 mg QD | MLN0128 4 mg QD | MLN0128 6 mg QD | MLN0128 7 mg QD | MLN0128 7 mg QW | MLN0128 10 mg QW | MLN0128 15 mg QW | MLN0128 20 mg QW | MLN0128 30mg QW | MLN0128 40 mg QW | MLN0128 6 mg QDx3dQW | MLN0128 9 mg QDx3d QW | MLN0128 12 mg QDx3d QW | MLN0128 16 mg QDx3d QW | MLN0128 20 mg QDx3dQW | MLN0128 7 mg QDx5dQW | MLN0128 10 mg QDx5dQW | MLN0128 13 mg QDx5dQW |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 2.0 (2.00 to 2.05) | 2.0 (0.98 to 4.00) | 1.0 (0.50 to 4.17) | 1.5 (0.50 to 7.57) | 2.1 (0.52 to 8.00) | 1.0 (1.00 to 1.97) | 2.0 (1.07 to 2.00) | 2.0 (1.00 to 2.15) | 1.0 (1.00 to 4.00) | 2.4 (1.00 to 4.53) | 0.6 (0.50 to 1.15) | 1.1 (0.55 to 4.33) | 2.0 (0.55 to 4.05) | 2.1 (0.50 to 8.67) | 3.1 (0.53 to 4.05) | 1.2 (0.50 to 4.08) | 4.0 (0.53 to 4.33) | 2.1 (1.08 to 8.00) |
| Cycle 2 Day 1 | 2.0 (1.97 to 2.00) | 3.8 (1.00 to 4.03) | 2.0 (1.03 to 4.42) | 4.0 (1.00 to 4.03) | 1.02 (1.02 to 1.02) | 2.9 (1.80 to 4.00) | 2.0 (2.00 to 8.00) | 4.0 (4.00 to 4.00) | 4.0 (1.03 to 7.92) | 2.0 (1.00 to 8.00) | 4.0 (1.00 to 4.00) | 2.1 (0.50 to 7.57) | 3.7 (1.00 to 4.18) | 2.1 (0.53 to 8.00) | 1.0 (1.00 to 1.00) | 1.5 (0.97 to 7.42) | 2.0 (0.52 to 3.58) | 2.02 (2.02 to 2.02) |
No measurements were reported for this outcome.
P4EBP, PAKT and PS6 were assayed in skin biopsies. A negative percentage change from Baseline indicates improvement.
| percentage change | MLN0128 QD | MLN0128 QW | MLN0128 QDx3d QW | MLN0128 QDx5d QW |
|---|---|---|---|---|
| p4EBP1 | -64.1 ± 47.65 | -15.5 ± 378.88 | -99.5 ± 2.75 | 87.4 ± 43.83 |
| pAKT | 27.1 ± 73.78 | 26.9 ± 139.75 | 73.3 ± 115.55 | 168.9 ± 514.88 |
| pS6 | -50.2 ± 43.89 | -42.7 ± 59.64 | -68.2 ± 37.98 | -82.5 ± 12.15 |
Collected over All cause-mortality were collected throughout the study; SAEs and Other (non-serious) were collected from the first dose of study drug plus 30 days after last dose of study drug (Up to approximately 244 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MLN0128 QD | 3/31 (9.7%) | 13/31 (41.9%) | 31/31 (100%) |
| MLN0128 QW | 2/30 (6.7%) | 10/30 (33.3%) | 30/30 (100%) |
| MLN0128 QDx3d QW | 2/33 (6.1%) | 17/33 (51.5%) | 33/33 (100%) |
| MLN0128 QDx5d QW | 0/22 (0%) | 10/22 (45.5%) | 22/22 (100%) |
| MLN0128 5 mg QD | 2/39 (5.1%) | 19/39 (48.7%) | 39/39 (100%) |
| MLN0128 30 mg QW | 2/17 (11.8%) | 6/17 (35.3%) | 17/17 (100%) |
| MLN0128 40 mg QW | 3/26 (11.5%) | 9/26 (34.6%) | 26/26 (100%) |
| Event | MLN0128 QD | MLN0128 QW | MLN0128 QDx3d QW | MLN0128 QDx5d QW | MLN0128 5 mg QD | MLN0128 30 mg QW | MLN0128 40 mg QW |
|---|---|---|---|---|---|---|---|
| StomatitisGastrointestinal disorders | 0/31 | 0/30 | 4/33 | 2/22 | 0/39 | 0/17 | 1/26 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/31 | 0/30 | 0/33 | 0/22 | 0/39 | 2/17 | 1/26 |
| AstheniaGeneral disorders | 0/31 | 0/30 | 3/33 | 1/22 | 0/39 | 0/17 | 0/26 |
| Abdominal painGastrointestinal disorders | 1/31 | 0/30 | 0/33 | 1/22 | 3/39 | 0/17 | 0/26 |
| DiarrhoeaGastrointestinal disorders | 1/31 | 0/30 | 0/33 | 0/22 | 0/39 | 0/17 | 2/26 |
| DehydrationMetabolism and nutrition disorders | 0/31 | 0/30 | 1/33 | 0/22 | 0/39 | 0/17 | 2/26 |
| AnaemiaBlood and lymphatic system disorders | 1/31 | 0/30 | 0/33 | 0/22 | 1/39 | 1/17 | 2/26 |
| Acute kidney injuryRenal and urinary disorders | 0/31 | 0/30 | 0/33 | 0/22 | 3/39 | 0/17 | 2/26 |
| Mental status changesPsychiatric disorders | 0/31 | 0/30 | 0/33 | 0/22 | 1/39 | 0/17 | 2/26 |
| PneumoniaInfections and infestations | 1/31 | 2/30 | 1/33 | 0/22 | 2/39 | 0/17 | 0/26 |
| Event | MLN0128 QD | MLN0128 QW | MLN0128 QDx3d QW | MLN0128 QDx5d QW | MLN0128 5 mg QD | MLN0128 30 mg QW | MLN0128 40 mg QW |
|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 10/31 | 9/30 | 15/33 | 7/22 | 25/39 | 11/17 | 24/26 |
| HyperglycaemiaMetabolism and nutrition disorders | 26/31 | 18/30 | 22/33 | 12/22 | 18/39 | 12/17 | 20/26 |
| NauseaGastrointestinal disorders | 16/31 | 22/30 | 24/33 | 13/22 | 21/39 | 12/17 | 20/26 |
| VomitingGastrointestinal disorders | 12/31 | 20/30 | 20/33 | 12/22 | 12/39 | 9/17 | 20/26 |
| StomatitisGastrointestinal disorders | 11/31 | 10/30 | 22/33 | 13/22 | 19/39 | 9/17 | 11/26 |
| Decreased appetiteMetabolism and nutrition disorders | 13/31 | 12/30 | 20/33 | 9/22 | 20/39 | 7/17 | 14/26 |
| DiarrhoeaGastrointestinal disorders | 14/31 | 10/30 | 17/33 | 9/22 | 20/39 | 9/17 | 11/26 |
| AstheniaGeneral disorders | 7/31 | 15/30 | 13/33 | 10/22 | 7/39 | 2/17 | 5/26 |
| ConstipationGastrointestinal disorders | 1/31 | 6/30 | 6/33 | 3/22 | 10/39 | 8/17 | 10/26 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 3/31 | 0/30 | 1/33 | 2/22 | 17/39 | 4/17 | 3/26 |
All Participants as Treated (ASaT) population included all participants who received at least 1 dose of MLN0128.
| Age, Continuous(years) | MLN0128 QD | MLN0128 QW | MLN0128 QDx3d QW | MLN0128 QDx5d QW | MLN0128 5 mg QD | MLN0128 30 mg QW | MLN0128 40 mg QW | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 59.7 (24 to 75) | 53.8 (34 to 89) | 56.1 (36 to 87) | 58.1 (32 to 75) | 58.8 (30 to 81) | 59.7 (32 to 76) | 63.2 (44 to 80) | 58.31 (24 to 89) |
| Sex: Female, Male(Participants) | MLN0128 QD | MLN0128 QW | MLN0128 QDx3d QW | MLN0128 QDx5d QW | MLN0128 5 mg QD | MLN0128 30 mg QW | MLN0128 40 mg QW | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 16 | 18 | 22 | 13 | 16 | 6 | 14 | 105 |
| Male | 15 | 12 | 11 | 9 | 23 | 11 | 12 | 93 |
| Ethnicity (NIH/OMB)(Participants) | MLN0128 QD | MLN0128 QW | MLN0128 QDx3d QW | MLN0128 QDx5d QW | MLN0128 5 mg QD | MLN0128 30 mg QW | MLN0128 40 mg QW | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 11 | 11 | 7 | 9 | 8 | 1 | 2 | 49 |
| Not Hispanic or Latino | 20 | 19 | 26 | 13 | 30 | 16 | 24 | 148 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | MLN0128 QD | MLN0128 QW | MLN0128 QDx3d QW | MLN0128 QDx5d QW | MLN0128 5 mg QD | MLN0128 30 mg QW | MLN0128 40 mg QW | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 3 | 0 | 0 | 0 | 0 | 6 |
| White | 28 | 29 | 30 | 22 | 37 | 17 | 25 | 188 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | MLN0128 QD | MLN0128 QW | MLN0128 QDx3d QW | MLN0128 QDx5d QW | MLN0128 5 mg QD | MLN0128 30 mg QW | MLN0128 40 mg QW | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 21 | 18 | 19 | 12 | 32 | 15 | 25 | 142 |
| Spain | 10 | 12 | 14 | 10 | 7 | 2 | 1 | 56 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
Ran from Jan 2010 to primary completion in Feb 2019, 109 months.
Results were first posted in Apr 2020, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sapanisertib
Millennium Pharmaceuticals, Inc. →